Blood Cancer Screening
Blood Cancer Screening - Related Videos
03:50
CTC Isolation from a Whole Blood Sample: A Method to Obtain CTCs from Murine Colorectal Cancer Model
0 Views •
2023
This video describes a detailed protocol for isolating circulating tumor cells from the whole blood sample of a euthanized colorectal tumor mouse model. These isolated CTCs can be cultured and used for intended downstream analysis.
06:19
Screening Ion Channels in Cancer Cells
0 Views •
Cited by 1 •
2023
The pharmacological targeting of ion channels is a promising approach to treating solid tumors. Detailed protocols are provided for characterizing ion channel function in cancer cells and assaying the effects of ion channel modulators on cancer viability.
03:23
Cell Death Screening Using DAPI Staining: A Method for Rapid Screening of IR Induced Clonogenic Cell Death in Cancerous Cell Lines
0 Views •
2023
This video demonstrates the methodology to screen for major cell death profiles in ionizing radiation (IR) induced cancer cell lines using DAPI staining assay. The DAPI-stained nuclei of target cells undergoing cell death exhibit distinct morphologies and can be easily identified by fluorescence microscopy.
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
0 Views •
Cited by 6 •
2013
Achieving a systems level understanding of cellular processes is a goal of modern-day cell biology. We describe here strategies for multiplexing luciferase reporters of various cellular function end-points to interrogate gene function using genome-scale RNAi libraries.
08:50
Genetic Screens
0 Views •
2023
Genetic screens are critical tools for defining gene function and understanding gene interactions. Screens typically involve mutating genes and then assessing the affected organisms for phenotypes of interest. The process can be “forward”, where mutations are generated randomly to identify unknown genes responsible for the phenotypes, or it can be “reverse”, where specific genes are targeted for mutation to observe what phenotypes are produced.Here, JoVE reviews various types of genetic...
FAQs
An initial complete blood count measures blood-cell patterns, while a peripheral blood smear allows cells to be examined for abnormalities in appearance. Used together, they can indicate that further evaluation is warranted, but they do not always provide the full characterization needed. This pairing therefore functions as an initial assessment rather than a complete diagnostic workup.
These methods add different kinds of information to initial blood findings. Flow cytometry helps characterize abnormal cells, whereas cytogenetic and molecular studies assess genetic alterations. Bone marrow examination provides another level of evaluation when results or symptoms raise concern. Selecting these tests sequentially helps connect an abnormal signal with disease classification and risk assessment.
Blood cancer screening differs from screening programs for conditions with established routine population testing. For most blood cancers, broad testing of people without relevant clinical indications is not widely established. Instead, clinicians may consider symptoms, clinical findings, family history, or treatment-monitoring needs when deciding whether evaluation is appropriate. This approach directs assessment toward meaningful clinical questions.
Test results can serve purposes beyond initial recognition. During treatment monitoring, blood-based and molecular findings may help assess whether disease-associated abnormalities remain relevant to the patient’s course. The same testing framework can also support risk assessment and therapy selection, linking laboratory evidence to management decisions. Interpretation depends on the clinical context and the specific information each method provides.
A practical evaluation commonly begins with a complete blood count and peripheral blood smear when clinical findings prompt concern. If those results or the patient’s symptoms warrant deeper investigation, clinicians may add flow cytometry, cytogenetic or molecular testing, and possibly bone marrow examination. The sequence is guided by initial findings and the question being investigated, rather than by one universal testing panel.
Testing may be considered when clinical findings or symptoms suggest an abnormal blood-cell process, when family history changes the level of concern, or when treatment requires monitoring. Because routine population screening is not widely established for most blood cancers, the decision should be individualized rather than based solely on having no symptoms. Clinical context helps determine which evaluation is appropriate.
The combined results may help determine whether further evaluation is needed, characterize abnormal cells, identify genetic alterations, and support classification of a blood cancer. They can also contribute to risk assessment and therapy selection. These outcomes make testing useful across recognition, diagnostic refinement, and ongoing medical management, rather than only at the first point of concern.